At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 15, 2026 at 16:01 ET
Nkarta announced FDA agreement on protocol amendments for its Ntrust-1 and Ntrust-2 trials, enabling outpatient dosing, redosing flexibility, and expansion into rheumatoid arthritis. These changes reduce patient burden and broaden trial accessibility, supporting clinical development of its CAR-NK therapy NKX019 for autoimmune diseases.
- FDA agreed to protocol amendments allowing outpatient administration of NKX019 with monitoring reduced from 24 hours to 2 hours
- Option to re-dose patients added in both Ntrust-1 and Ntrust-2 trials
- Rheumatoid arthritis cohort to be added to Ntrust-2 trial
- No geographic monitoring requirements remain, reducing patient burden
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access